EU Marketing Submission

Futura Medical PLC
28 November 2005


For immediate release                                           28 November 2005


                                Futura Medical plc
                 Announces the submission of CSD500 device dossier
                          for EU marketing author     isation

Futura Medical plc (AIM: FUM), the pharmaceutical drug and medical device group
that develops innovative products for the sexual healthcare market, announces
submission of the regulatory dossier for the condom safety device CSD500.  This
dossier has been submitted to the relevant Notified Body/Competent Authority for
seeking market authorisation in the European Union.

CSD500 will be marketed as a Durex(TM) branded condom containing an active
compound which will enhance the barrier function of the condom. The active
compound will help healthy men to maintain a fuller and firmer erection during
sexual intercourse, thereby helping to reduce the risk of condom slippage.

Durex(TM) has a 29% share of the global market for branded condoms with sales of
£146 million in 2004. Seventy nine percent (79%) of SSL group sales in 2004 were
in Europe where the initial marketing authorisations will be sought for CSD500.
Although the precise terms of the deal are confidential, Futura will receive
royalty based payments from sales of the CSD500 condom.

James Barder, Chief Executive of Futura, said: 'We are delighted to reach this
major milestone for the first of our three leading products which will reinforce
our position as an innovative sexual health company. The dossier submission
demonstrates Futura's ability to work closely with our commercial partners to
overcome technical challenges and to drive investor value.  Consumers' sexual
health is a key issue for medical authorities with the increase in Sexually
Transmitted Infections such as chlamydia. In this context, combined with the
evolving market for sexual health products and working with Durex(TM) as the
leading global condom brand, we believe CSD500 will generate significant 
demand.'

Chris Bunniss, SSL's group marketing and innovations director, said: 'Durex(TM) is
no longer a brand associated purely with safer sex, but better sex too. We are
constantly looking at the development of innovative products in the area of
sexual enhancement.  We believe CSD500 could become an exciting addition and
leading product within the Durex(TM) range that will help to improve the sex lives
of our customers.'

For further information:
Futura Medical plc
James Barder, Chief Executive                          Tel: [phone]
mail to: [e-mail]                www.futuramedical.co.uk

Media enquiries:
Buchanan Communications
Mark Court / Tim Anderson / Rebecca Dietrich          Tel: [phone]


Notes to Editors:

Futura Medical plc

Futura Medical is an AIM-listed pharmaceutical drug and medical device group
developing innovative products for sexual health.  The Company is developing a
portfolio of products with the intention of licensing their manufacture and
distribution to major pharmaceutical and healthcare groups.   Exclusive
worldwide distribution agreements have already been signed in respect of
Futura's two condom safety products, CSD500 and FLD500, with SSL International
plc, the makers of Durex(TM) condoms.


For further information please visit www.futuramedical.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange